Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5852536 | 1.00 | IDO1 (0.50) | IDO1ADRA2AADRA1AADRA2BADRA2C | |
| SCHEMBL5852603 | 0.88 | IDO1 (0.47) | IDO1 | |
| SCHEMBL7108519 | 0.88 | IDO1 (0.47) | IDO1 | |
| SCHEMBL1109727 | 0.88 | IDO1 (0.47) | IDO1 | |
| SCHEMBL28971366 | 0.88 | IDO1 (0.47) | IDO1 | |
| SCHEMBL2610198 | 0.77 | HTR2A (0.41) | IDO1LMNAOPRM1KMT2A | |
| SCHEMBL2370159 | 0.74 | KMT2A (0.46) | KMT2A | |
| SCHEMBL145977 | 0.74 | IDO1 (0.57) | IDO1ADRA2AADRA1ACYP2D6LMNA | |
| SCHEMBL8201616 | 0.74 | KMT2A (0.46) | KMT2A | |
| SCHEMBL5061699 | 0.74 | KMT2A (0.46) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812184-B2 | Production method of optically active epoxy compound, complex used for the method and production method of the complex | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-10-12 | — | — | US | disclosed |
| US-7812184-B2 | Production method of optically active epoxy compound, complex used for the method and production method of the complex | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-10-12 | — | — | US | disclosed |
| US-7659281-B2 | HMG-CoA reductase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-09 | — | — | US | disclosed |
| US-7659281-B2 | HMG-CoA reductase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-09 | — | — | US | disclosed |
| US-20080234502-A1 | Production method of optically active epoxy compound, complex used for the method and production method of the complex | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-09-25 | — | — | US | disclosed |
| US-20080234502-A1 | Production method of optically active epoxy compound, complex used for the method and production method of the complex | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-09-25 | — | — | US | disclosed |
| US-20070249583-A1 | HMG-CoA reductase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-25 | — | — | US | disclosed |
| US-20070249583-A1 | HMG-CoA reductase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-25 | — | — | US | disclosed |
| EP-0329563-B1 | BENZOCYCLOHEXANE AND BENZOCYCLOHEPTANE DERIVATIVES AND THEIR SALTS, PROCESS AND INTERMEDIATES FOR THEIR PREPARATION, THEIR USE AS MEDICINES AND COMPOSITIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1993-04-21 | — | — | EP | disclosed |
| US-5130329-A | Amino, amide substituted compounds | ROUSSEL UCLAF (FR) | 1992-07-14 | — | — | US | disclosed |
| US-5068244-A | Benzcarbocyclic amides with nitro groups | ROUSSEL UCLAF (FR) | 1991-11-26 | — | — | US | disclosed |
| EP-0329563-A2 | Benzocyclohexane and benzocycloheptane derivatives and their salts, process and intermediates for their preparation, their use as medicines and compositions containing them | ROUSSEL-UCLAF (FR) | 1989-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249583-A1 | HMG-CoA reductase inhibitors | HMGCR, LDLR, PCSK9 | IDO1 3023/4885ADRA2A 1669/4885ADRA1A 1002/4885 |
| US-20080234502-A1 | Production method of optically active epoxy compound, complex used for the method and production method of the complex | EPOR, OSTC, CYP51A1 | IDO1 2534/4885ADRA2A 1825/4885ADRA1A 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.